Synergy Pharmaceuticals commences pivotal plecanatide CIC trial

• Synergy Pharmaceuticals (SGYP +2.5%) initiates a Phase 3 pivotal trial of plecanatide in CIC. Primary endpoint: Proportion of patients who are overall responders.
• The company is confident the GC-C agonist is "best-in-class."
• Top-line data from an ongoing Phase 2b study of plecanatide in IBS-C is due in Q1 2014. (PR)